Human Papillomavirus in Cervical Cancer and Pre-cancer in Switzerland: The CIN3+Plus Study (CIN3+plus)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
18 Years and older (Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Women with histologically confirmed CIN3+ lesions
Participant is willing and able to give informed consent for participation in the study.
Participant is literate in German, French, Italian or English.
Female, aged 18 years or above.
Histologically confirmed CIN3+ lesions, i.e. CIN3, adenocarcinoma in situ and invasive carcinoma of the cervix.
Participant resides in the canton Zurich, Geneva, Basel, Baselland, Luzern or Ticino.